Pfizer wins obesity drug prize
Digest more
2don MSN
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...
On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has ...
U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...
Metsera said it expects the Pfizer deal to close promptly after a stockholder meeting scheduled for this coming Thursday ...
Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...
Better still, if interest rates drop, as they're generally expected to over the coming year, the interest income you'll get ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback